Amgen (AMGN) Stock Forecast & Price Target

$267.10 -3.09 (-1.14%)

As of 01/14/2025 04:00 PM Eastern

Amgen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 27 Analyst Ratings

Sell
2

Hold
12

Buy
13

Based on 27 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 27 analysts, 2 have given a sell rating, 12 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for AMGN.

Consensus Price Target

$314.91
17.90% Upside

According to the 27 analysts' twelve-month price targets for Amgen, the average price target is $314.91. The highest price target for AMGN is $405.00, while the lowest price target for AMGN is $195.00. The average price target represents a forecasted upside of 17.90% from the current price of $267.10.

Get the Latest News and Ratings for AMGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amgen and its competitors.

AMGN Analyst Ratings Over Time

Type	Current Forecast 1/16/24 to 1/15/25	1 Month Ago 12/17/23 to 12/16/24	3 Months Ago 10/18/23 to 10/17/24	1 Year Ago 1/16/23 to 1/16/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	13 Buy rating(s)
Hold	12 Hold rating(s)	12 Hold rating(s)	12 Hold rating(s)	6 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$314.91	$319.68	$329.48	$285.71
Forecasted Upside	17.90% Upside	19.96% Upside	2.54% Upside	-5.85% Downside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amgen Stock vs. The Competition

Type	Amgen	Medical Companies	S&P 500
Consensus Rating Score	2.44	2.82	2.52
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	17.90% Upside	24,950.25% Upside	14.85% Upside
News Sentiment Rating	Positive News See Recent AMGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/10/2025	Wells Fargo & Company 3 of 5 stars	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$335.00 ➝ $280.00	+6.26%
1/8/2025	Truist Financial 2 of 5 stars	S. Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$333.00 ➝ $298.00	+13.71%
1/2/2025	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$344.00 ➝ $310.00	+18.94%
1/2/2025	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight	$310.00	+18.94%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underperform	$256.00	-7.79%
11/27/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$335.00 ➝ $310.00	+10.71%
Get the Latest News and Ratings for AMGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.
11/27/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$305.00 ➝ $285.00	+1.78%
11/27/2024	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$200.00 ➝ $195.00	-30.36%
11/27/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$349.00 ➝ $302.00	+7.85%
11/27/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$360.00 ➝ $330.00	+17.85%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/12/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$380.00 ➝ $380.00	+28.07%
11/12/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$335.00 ➝ $326.00	+1.31%
10/22/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$405.00 ➝ $405.00	+28.41%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$381.00 ➝ $383.00	+20.14%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$380.00	+18.15%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$300.00 ➝ $315.00	-0.48%
9/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underperform ➝ Underperform	$215.00 ➝ $215.00	-31.92%
9/16/2024	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$380.00 ➝ $380.00	+22.53%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$310.00 ➝ $303.00	-6.67%
6/27/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$300.00 ➝ $340.00	+8.87%
5/9/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$223.00 ➝ $235.00	-23.53%
5/3/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$336.00 ➝ $355.00	+12.91%
3/28/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
2/7/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/7/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$313.00 ➝ $350.00	+10.73%
12/21/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$264.00 ➝ $320.00	+16.29%
10/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$270.00	-3.69%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$320.00	+25.98%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$220.00 ➝ $200.00	-10.66%
2/2/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$282.00 ➝ $267.00	+8.36%
2/1/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$307.00 ➝ $289.00	+14.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:28 AM ET.

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, January 10, 2025. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

Amgen
Bull Case

Here are some ways that investors could benefit from investing in Amgen Inc.:

Amgen Inc. recently reported earnings per share (EPS) of $5.58, exceeding the consensus estimate of $5.11, indicating strong financial performance and effective management.
The company has shown a year-over-year revenue increase of 23.2%, reflecting robust growth and demand for its therapeutics.
Amgen Inc. has a current stock price of $263.38, which may present a buying opportunity for investors looking for growth potential in the biotech sector.
The recent increase in the quarterly dividend from $2.25 to $2.38 per share demonstrates Amgen Inc.'s commitment to returning value to shareholders, with an annualized yield of 3.61%.
Analysts have a consensus rating of "Hold" with a price target around $319.68, suggesting potential upside for investors who buy at current levels.

Amgen
Bear Case

Investors should be bearish about investing in Amgen Inc. for these reasons:

Two analysts have rated the stock with a sell rating, indicating some skepticism about its future performance.
Bank of America has issued an "underperform" rating with a price target of $256.00, suggesting that the stock may not perform well compared to its peers.
The company's high debt-to-equity ratio of 7.55 raises concerns about financial leverage and the potential risks associated with high debt levels.
Amgen Inc. has a payout ratio of 121.90%, which means it is paying out more in dividends than it is earning, potentially unsustainable in the long term.
Recent downgrades from analysts, including a shift from a "buy" to a "hold" rating, may indicate a lack of confidence in the stock's short-term prospects.

AMGN Forecast - Frequently Asked Questions

: According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $314.91, with a high forecast of $405.00 and a low forecast of $195.00.
: 27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 12 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
: According to analysts, Amgen's stock has a predicted upside of 17.90% based on their 12-month stock forecasts.
: Over the previous 90 days, Amgen's stock had 1 upgrade by analysts.
: Amgen has been rated by research analysts at Bank of America, Cantor Fitzgerald, Citigroup, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, Leerink Partners, Piper Sandler, Piper Sandler Companies, Redburn Partners, Royal Bank of Canada, Sanford C. Bernstein, TD Cowen, Truist Financial, UBS Group, Wells Fargo & Company, William Blair, and Wolfe Research in the past 90 days.
: Analysts like Amgen less than other "medical" companies. The consensus rating for Amgen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:AMGN) was last updated on 1/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amgen (AMGN) Stock Forecast & Price Target